Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)

Completed · Phase 1

Conditions studied: Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema

In brief

The primary objective of the study is to investigate the safety and tolerability of intravitreal (IVT) REGN910-3 and IVT REGN910 in patients with neovascular age-related macular degeneration (AMD), and separately in patients with diabetic macular edema (DME).

Key facts

Study ID

NCT01997164

Run by

Regeneron Pharmaceuticals

People needed

20

Starts

2014-11-01

Expected to finish

2015-10-01

Last updated by the study team

2016-01-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Beverly Hills, California, United States
• Study site — Winter Haven, Florida, United States
• Study site — Boston, Massachusetts, United States
• Study site — West Columbia, South Carolina, United States
• Study site — Abilene, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.